Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aspirin, quantity: 25 mg; dipyridamole, quantity: 200 mg - capsule, modified release - excipient ingredients: triacetin; pregelatinised maize starch; sucrose; microcrystalline cellulose; purified talc; acacia; tartaric acid; hypromellose; gelatin; hypromellose phthalate; methacrylic acid copolymer; stearic acid; iron oxide red; iron oxide yellow; titanium dioxide; povidone; sodium benzoate; potable water; simethicone; cetostearyl alcohol - for the prevention of recurrent ischaemic stroke and transient ischaemic attacks.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aspirin, quantity: 25 mg; dipyridamole, quantity: 200 mg - capsule, modified release - excipient ingredients: hypromellose; gelatin; triacetin; methacrylic acid copolymer; purified talc; microcrystalline cellulose; hypromellose phthalate; acacia; tartaric acid; pregelatinised maize starch; sucrose; stearic acid; iron oxide red; iron oxide yellow; titanium dioxide; povidone; sodium benzoate; potable water; simethicone; cetostearyl alcohol - for the prevention of recurrent ischaemic stroke and transient ischaemic attacks.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,dipyridamole -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aspirin, quantity: 25 mg; dipyridamole, quantity: 200 mg - capsule, modified release - excipient ingredients: hypromellose phthalate; gelatin; methacrylic acid copolymer; microcrystalline cellulose; tartaric acid; purified talc; pregelatinised maize starch; sucrose; hypromellose; triacetin; acacia; stearic acid; iron oxide red; iron oxide yellow; titanium dioxide; povidone; sodium benzoate; potable water; simethicone; cetostearyl alcohol - for the prevention of recurrent ischaemic stroke and transient ischaemic attacks.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aspirin,clopidogrel hydrogen sulfate -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Yhdysvallat - englanti - NLM (National Library of Medicine)

american health packaging - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin, usp is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis and nasal polyps. aspirin, usp may cause severe urticaria, angioedema or bronchospasm. do not use aspirin, usp in children or teenagers with viral infections because of the risk of reye syndrome. teratogenic effects, pregnancy category d. [see warnings and precautions (5.4)]. aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pr

Yhdysvallat - englanti - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. aspirin may cause severe urticaria, angioedema or bronchospasm. do not use aspirin in children or teenagers with viral infections because of the risk of reye syndrome. teratogenic effects , pregnancy category d. [see warnings and precautions (5.4) ]. aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pregnancy [se

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -